Effects of C7 substitutions in a high affinity microtubule-binding taxane on antitumor activity and drug transport.

[1]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[2]  F. Sharom,et al.  ABC efflux pump-based resistance to chemotherapy drugs. , 2009, Chemical reviews.

[3]  R. Himes,et al.  Paclitaxel succinate analogs: Anionic and amide introduction as a strategy to impart blood-brain barrier permeability. , 2008, Bioorganic & medicinal chemistry letters.

[4]  Xiaoguang Chen,et al.  Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. , 2008, Cancer letters.

[5]  Federico Gago,et al.  Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. , 2008, Chemistry & biology.

[6]  G. Scambia,et al.  New taxanes in development , 2008 .

[7]  M. Botta,et al.  Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes , 2007, ChemMedChem.

[8]  I. Barasoain,et al.  Overcoming Tumor Drug Resistance with High‐Affinity Taxanes: A SAR Study of C2‐Modified 7‐Acyl‐10‐Deacetyl Cephalomannines , 2007, ChemMedChem.

[9]  E. Rowinsky,et al.  Novel agents that target tublin and related elements. , 2006, Seminars in oncology.

[10]  R. Himes,et al.  Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells. , 2006, Bioorganic & medicinal chemistry letters.

[11]  R. Himes,et al.  Synthesis and interactions of 7-deoxy-, 10-deacetoxy, and 10-deacetoxy-7-deoxypaclitaxel with NCI/ADR-RES cancer cells and bovine brain microvessel endothelial cells. , 2006, Bioorganic & medicinal chemistry letters.

[12]  R. Himes,et al.  Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. , 2005, Journal of medicinal chemistry.

[13]  Susan Band Horwitz,et al.  Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.

[14]  C. Decker,et al.  Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. , 2001, Current opinion in chemical biology.

[15]  G Beck,et al.  Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. , 2001, Journal of pharmaceutical sciences.

[16]  M. Zucchetti,et al.  IDN5109, a taxane with oral bioavailability and potent antitumor activity. , 2000, Cancer research.

[17]  R. Himes,et al.  THE CHEMISTRY OF THE TAXANE DITERPENE : STEREOSELECTIVE REDUCTIONS OF TAXANES , 1998 .

[18]  P. Giannakakou,et al.  Synthesis and biological evaluation of 2-acyl analogues of paclitaxel (Taxol). , 1998, Journal of medicinal chemistry.

[19]  M. Yazdanian,et al.  Correlating Partitioning and Caco-2 Cell Permeability of Structurally Diverse Small Molecular Weight Compounds , 1998, Pharmaceutical Research.

[20]  Zhuming Zhang,et al.  Selective protection of the C(7) and C(10) hydroxyl groups in 10-deacetyl baccatin III , 1998 .

[21]  J. Díaz,et al.  Characterizing ligand-microtubule binding by competition methods. , 2007, Methods in molecular medicine.

[22]  W. Fang,et al.  Recent progress in structure activity relationship and mechanistic studies of taxol analogues. , 2005, Mini reviews in medicinal chemistry.